ATR-101

CAS No. 133825-81-7

ATR-101( PD-132301 | PD132301-2 | ATR 101 | Nevanimibe )

Catalog No. M11357 CAS No. 133825-81-7

ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 192 In Stock
10MG 267 In Stock
25MG 417 In Stock
50MG 533 In Stock
100MG 708 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ATR-101
  • Note
    Research use only, not for human use.
  • Brief Description
    ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM.
  • Description
    ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM; induces H295R cell apoptosis, causes mitochondrial hyperpolarization, reactive oxygen release, and ATP depletion, caspase-3/7 activation, and membrane permeabilization; decreases the formation of cholesteryl esters and increases FC levels in H295R adrenocortical carcinoma cells; inhibits the establishment and impeds the growth of ACC-derived H295R cell xenografts in mice; orally active.Cushing Disease Phase 2 Clinical(In Vitro):Coincubation of Nevanimibe hydrochloride (PD-132301 hydrochloride; ATR101 hydrochloride; 3 nM-30 μM) and Cholesterol markedly increases toxicity in a dose-dependent manner, where 3 nM Nevanimibe in the presence of 60 μg/mL Cholesterol reduces survival by 60% after 24 hours. All doses of Nevanimibe (3 nM-30 μM) induces cytoxicity in the presence of Cholesterol, whereas treatment with Cholesterol in the absence of Nevanimibe has no effect on cell viability.
  • In Vitro
    Cell Cytotoxicity Assay Cell Line:The H295R and HAC clone 15 (HAC15) human ACC cell lines Concentration:3 nM-30 μM Incubation Time:24 hours Result:3 nM-3 μM exhibited no toxicity, whereas 30 μM treatment reduced survival by approximately 40% within 24 hours.
  • In Vivo
    ——
  • Synonyms
    PD-132301 | PD132301-2 | ATR 101 | Nevanimibe
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Other Targets
  • Research Area
    Endocrinology
  • Indication
    Cushing Disease

Chemical Information

  • CAS Number
    133825-81-7
  • Formula Weight
    458.09
  • Molecular Formula
    C27H40ClN3O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 41.67 mg/mL. 90.97 mM
  • SMILES
    CC(C)C1=C(C(=CC=C1)C(C)C)NC(=O)NCC2(CCCC2)C3=CC=C(C=C3)N(C)C.Cl
  • Chemical Name
    1-(2,6-diisopropylphenyl)-3-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. LaPensee CR, et al. Endocrinology. 2016 May;157(5):1775-88. 2. Trivedi BK, et al. J Med Chem. 1994 May 27;37(11):1652-9. 3. Cheng Y, et al. Endocr Relat Cancer. 2016 Apr;23(4):1-19.
molnova catalog
related products
  • Carbocisteine

    Carbocysteine is a compound formed when the iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action.

  • Eucomic acid

    Eucomic acid showed the best inhibitory activity against the P. falciparum 3D7, a well-known chloroquine-sensitive strain.

  • Eprodisate disodium

    Eprodisate Disodium is the orally available disodium salt form of Eprodisate, a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis.